Role of platelets in NOX2 activation mediated by TNFα in heart failure

Internal and Emergency Medicine

Volumn 9, Issue 2, 2014, Pages 179-185

  Cangemi, Roberto ^a   Celestini, Andrea ^a   Del Ben, Maria ^a   Pignatelli, Pasquale ^a   Carnevale, Roberto ^a   Proietti, Marco ^a   Calabrese, Cinzia Myriam ^a   Basili, Stefania ^a   Violi, Francesco ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Heart failure; NADPH oxidase; Oxidative stress; TNF

Indexed keywords

CYBB PROTEIN, HUMAN; MEMBRANE PROTEIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TUMOR NECROSIS FACTOR ALPHA;

AGED; CELL CULTURE; CROSS-SECTIONAL STUDY; FEMALE; HEART FAILURE; HUMAN; MALE; PHYSIOLOGY; THROMBOCYTE;

AGED; BLOOD PLATELETS; CELLS, CULTURED; CROSS-SECTIONAL STUDIES; FEMALE; HEART FAILURE; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; NADPH OXIDASE; REACTIVE OXYGEN SPECIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84894496314     PISSN: 18280447     EISSN: 19709366     Source Type: Journal    
DOI: 10.1007/s11739-012-0837-2     Document Type: Article

References (23)

1. Dickstein K, Cohen-Solal A, Filippatos G et al (2008) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 29: 2388-2442.
2. Blum A (2009) Heart failure-new insights. Isr Med Assoc J 11: 105-111.
3. Mann DL (2002) Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 91: 988-998.
4. Levine B, Kalman J, Mayer L, Fillit HM, Packer M (1990) Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 323: 236-241.
5. Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL (1996) Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 27: 1201-1206.
6. 2-production. Thromb Haemost 90: 317-325.
7. Pignatelli P, Cangemi R, Celestini A et al (2008) Tumour necrosis factor alpha upregulates platelet CD40L in patients with heart failure. Cardiovasc Res 78: 515-522.
8. Moe KT, Yin NO, Naylynn TM et al (2011) Nox2 and Nox4 mediate tumour necrosis factor-alpha-induced ventricular remodelling in mice. J Cell Mol Med 15: 2601-2613.
9. Pignatelli P, Sanguigni V, Lenti L, Ferro D, Finocchi A, Rossi P, Violi F (2004) gp91phox-dependent expression of platelet CD40 ligand. Circulation 110: 1326-1329.
10. Pignatelli P, Carnevale R, Cangemi R, Loffredo L, Sanguigni V, Stefanutti C, Basili S, Violi F (2010) Atorvastatin inhibits gp91phox circulating levels in patients with hypercholesterolemia. Arterioscler Thromb Vasc Biol 30: 360-367.
11. Baj-Krzyworzeka M, Majka M, Pratico D et al (2002) Platelet-derived microparticles stimulate proliferation, survival, adhesion, and chemotaxis of hematopoietic cells. Exp Hematol 30: 450-459.
12. Pignatelli P, De Biase L, Lenti L et al (2005) Tumor necrosis factor-alpha as trigger of platelet activation in patients with heart failure. Blood 106: 1992-1994.
13. Blair P, Rex S, Vitseva O et al (2009) Stimulation of Toll-like receptor 2 in human platelets induces a thromboinflammatory response through activation of phosphoinositide 3-kinase. Circ Res 104: 346-354.
14. Pignatelli P, Carnevale R, Di Santo S et al (2011) Inherited human gp91phox deficiency is associated with impaired isoprostane formation and platelet dysfunction. Arterioscler Thromb Vasc Biol 31: 423-434.
15. Cave AC, Brewer AC, Narayanapanicker A, Ray R, Grieve DJ, Walker S, Shah AM (2006) NADPH oxidases in cardiovascular health and disease. Antioxid Redox Signal 8: 691-728.
16. Grieve DJ, Byrne JA, Siva A, Layland J, Johar S, Cave AC, Shah AM (2006) Involvement of the nicotinamide adenosine dinucleotide phosphate oxidase isoform Nox2 in cardiac contractile dysfunction occurring in response to pressure overload. J Am Coll Cardiol 47: 817-826.
17. Heymes C, Bendall JK, Ratajczak P, Cave AC, Samuel JL, Hasenfuss G, Shah AM (2003) Increased myocardial NADPH oxidase activity in human heart failure. J Am Coll Cardiol 41: 2164-2171.
18. Dworakowski R, Walker S, Momin A, Desai J, El-Gamel A, Wendler O, Kearney MT, Shah AM (2008) Reduced nicotinamide adenine dinucleotide phosphate oxidase-derived superoxide and vascular endothelial dysfunction in human heart failure. J Am Coll Cardiol 51: 1349-1356.
19. Ueland T, Aukrust P, Yndestad A et al (2005) Soluble CD40 ligand in acute and chronic heart failure. Eur Heart J 26: 1101-1107.
20. Stumpf C, Lehner C, Eskafi S et al (2003) Enhanced levels of CD154 (CD40 ligand) on platelets in patients with chronic heart failure. Eur J Heart Fail 5: 629-637.
21. Chung I, Choudhury A, Lip GY (2007) Platelet activation in acute, decompensated congestive heart failure. Thromb Res 120: 709-713.
22. Lip GY, Gibbs CR (1999) Does heart failure confer a hypercoagulable state? Virchow's triad revisited. J Am Coll Cardiol 33: 1424-1426.
23. Feldman AM, Combes A, Wagner D, Kadakomi T, Kubota T, Li YY, McTiernan C (2000) The role of tumor necrosis factor in the pathophysiology of heart failure. J Am Coll Cardiol 35: 537-544.